Drug Profile
Hib meningococcal group C vaccine - GSK
Alternative Names: Hib-MenC conjugated vaccine - GSK; Hib-MenC vaccine - GSK Biologicals; Hib-MenC-TT; Hib-MenC-TT conjugated vaccine - GSK; HibMenC; MenitorixLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Haemophilus vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemophilus infections; Meningococcal group C infections
Most Recent Events
- 25 Jan 2019 Hib meningococcal group C vaccine is not yet available for Haemophilus infections and Meningococcal group C infections (Prevention) in Belgium, Greece and Brazil
- 25 Jan 2019 Launched for Haemophilus infections in New Zealand, prior January 2019 (IM)
- 25 Jan 2019 Launched for Meningococcal group C infections in New Zealand, prior January 2019 (IM)